Sans IPO, Bayhill secures $350M in Genentech licensing deal
Months after giving up on its IPO hopes last year — when the market was especially brutal for lifescience companies — Bayhill Therapeutics has landed a licensing deal worth $25 million in upfront cash and equity with Genentech. It could bring in as much as… Continue Reading
Intradigm closes $21.4M for cancer therapeutics
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer.
The Palo Alto, Calif.-based company says it… Continue Reading
Intradigm lands $18.5M to advance oncology treatment
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, and existing investors Alta Partners, Frazier Healthcare Ventures,… Continue Reading
Life sciences briefing: Thursday, Nov. 1, 2007
Featured companies: Asteres, HemaQuest Pharmaceuticals, Nanosphere, Novalar Pharmaceuticals, Tranzyme Pharma
(UPDATED: Expanded items for Nanosphere, HemaQuest and Transzyme. Moved Novalar to a separate item here.)
Diagnostic maker Nanosphere prices IPO at low end of range, raises up to $113M — Nanosphere, a Northbrook, Ill., biotech focused on nanotech-derived diagnostics,… Continue Reading
Life sciences briefing: Wednesday, Sept. 26, 2007
Featured companies: Ablynx, Cardiosolutions, Carigent Thereapeutics, Elusys, Genome Corp., GlobeImmune, Novazone, Targanta Therapeutics, Waterfront Media
UPDATED at 5:45am on 9/27/07
GlobeImmune raises $41M for immune-system therapies — GlobeImmune, a Louisville, Colo., biotech focused on new forms of immunotherapy to treat viral infections and cancer, raised $41.2 million in… Continue Reading
Life sciences briefing: Wednesday, Aug. 29, 2007
(UPDATED at 3:10pm PT: See below.)
Featured companies: Agendia, EndoGastric Solutions, FlowCo, Gentris, MedManage Systems, ParagonDx, Presidio Pharmaceuticals, Xoova
Presidio Pharma raises $26M for viral treatments — San Francisco’s Presidio Pharmaceuticals, a biotech developing new antiviral drugs, raised $26 million in a second funding round. Investors included Panorama… Continue Reading
Funding roundup: Announcements that got away
Although I try to stay on top of events in the life sciences, announcements do sometimes manage to slip through the cracks. Some days, in fact, I end up triaging. Because the roots of this site — not to mention many of its readers —… Continue Reading
BioVeda China gets $10M from Eli Lilly venture fund
BioVeda China, an international VC fund focused on life science in China, raised $10 million from Lilly Asian Ventures, a spinoff of the Eli Lilly venture arm Lilly Ventures. The funds will be invested in local Chinese life-science companies.
From the BioVeda press release:
For the past… Continue Reading
Avid Radiopharmaceuticals, maker of imaging reagents, raises $26M for clinical trials
Avid Radiopharmaceuticals, a Philadelphia-based maker of “molecular imaging agents” that help highlight diseased tissue in various medical scans, raised $26 million in a third round to develop early-detection products for Alzheimer’s and Parkinson’s disease.
AllianceBernstein and Safeguard Scientifics led the round. Previous investors including Pfizer Strategic… Continue Reading